Fluidigm
In Brief This Week: Cepheid, Biocartis, Sight Diagnostics, Fluidigm, Co-Diagnostics, and More
News items for in vitro diagnostics industry for the week of Jan. 10, 2022.
Danaher, PerkinElmer, Cue Health, Others Announce Preliminary Q4 Earnings Results
Other companies reporting preliminary Q4 financial results included Fluidigm, SomaLogic, and T2 Biosystems.
Fluidigm Q3 Revenues Drop 29 Percent on Supply Chain Issues, Waning COVID-19 Testing
The company also lowered its full-year financial guidance and said its board of directors is undertaking a strategic review to maximize shareholder value.
Fluidigm Q2 Revenues Grow 19 Percent
The firm noted that its base product and service revenue (excluding COVID-19 testing) increased 33 percent year over year to $26.9 million.
Fluidigm Q1 Revenues Grow 19 Percent
The firm adjusted its 2021 revenue guidance range downward due to COVID-19 testing uncertainty, partially offset by expected growth in its core omics tools business.
Feb 11, 2021